Induction Chemotherapy Followed by Radiation Therapy Versus Surgery Followed by Concurrent Chemo-Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Shabbir Hussain A. Ali 1, Abdul Hafeez 1, Ayesha Javed 2, Mahwish Akhtar 3, Muhammad Jawaid Mallick 3

1. Oncology, Ziauddin University, Karachi, PAK 2. Oncology, Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN) Hospital, Karachi, PAK 3. Oncology, Baitul Sukoon Cancer Hospital and Hospice, Karachi, PAK

Corresponding author: Shabbir Hussain A. Ali, dr.shabbirhussain@zu.edu.pk

Abstract

Introduction

Squamous cell carcinoma of the oral cavity is one of the top 10 malignancies reported globally. Pakistan has a high incidence of oral cancers due to the prevailing poor lifestyle habits/addictions of Pakistanis, and most patients with squamous cell carcinoma present with stage III or IV locally advanced disease. Recommended guidelines indicate surgery as the mainstay of treatment followed by radiotherapy (RT). The addition of induction chemotherapy before surgery or radiation therapy might improve outcomes with increased locoregional control rates.

Methods

This was a retrospective cohort study comparing the outcomes between surgery followed by concurrent chemoradiotherapy (CCRT) and induction chemotherapy followed by RT. This study primarily aimed to evaluate progression-free survival (PFS) and determine the toxicity of chemotherapy.

Results

We found out that the mean PFS among patients undergoing surgery and CCRT and those receiving induction chemotherapy followed by RT were 6.40 (± 2.38) months and 7.6 (± 4.76) months, respectively.

Conclusion

Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by RT shows satisfactory results with acceptable toxicity. However, the results are not statistically significant but support the already published data on this treatment aspect of oral cavity cancers.

Categories: Otolaryngology, Radiation Oncology, Oncology

Keywords: oral cavity cancer, induction chemotherapy, tpf chemotherapy, concurrent chemo-radiation, radiation therapy

Introduction

Squamous cell carcinoma of the oral cavity is the sixth most common neoplasm worldwide. Its incidence varies across different parts of the world. Approximately 405,000 new cases of oral cancer are diagnosed worldwide annually, of which two-thirds are reported in developing countries. The incidence of oral cancer is significantly high in countries such as Pakistan, India, Sri Lanka, and Bangladesh. It accounts for up to 30% of newly diagnosed cases of cancer in developing countries, as opposed to 3% in the United Kingdom and 6% in France, confirming a higher incidence in economically deprived nations [1-2]. It is estimated that in the United States, in 2021, 35,540 new cases were diagnosed with oral cavity cancer, and 6,980 died of the same disease [3].

In developing countries, oral carcinoma is one of the most common cancers, probably due to the risky behaviors practiced in individuals living in these countries [4]. The age-standardized incidence of oral cancers in developing countries is approximately 4.6/100,000 per year. However, the incidence of such cancers is nearly 6.9/100,000 per year in developed countries. Although oral carcinoma has a lower incidence in developing countries, its mortality rate is higher in such low-income countries, at 2.7 per 100,000 compared to 2.3 per 100,000 in developed countries [5]. These statistics are probably due to the lack of incidence rates of oral cancer in South Asian countries where its incidence remains high and due to population differences. However, mortality due to oral cancers is low among men in most countries of Europe and Asia and continues to increase in eastern European countries such as Hungary and Slovakia [5].
Materials And Methods

This is a retrospective quasi-experimental study conducted in the oncology department of Ziauddin University Hospital. Data of previously treated patients with squamous cell carcinoma of the oral cavity were collected from the medical record department managed between 2010 and 2014 (Total 5 years).

These were further stratified according to our decided inclusion and exclusion criteria. Both men and women aged > 18 years and < 70 years with histologically confirmed, non-metastatic, locally advanced squamous cell carcinoma of the oral cavity (including the upper and lower lips, buccal mucosa, upper and lower alveolus, hard palate, part of the soft palate, anterior tongue, floor of the mouth, and retro-molar trigone) were included in the study. Performance status at the start of treatment was limited to the Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. Patients who were not treated previously with surgery, chemotherapy, or radiation therapy were included in this study. The patients shouldn’t have any other simultaneous cancer in the body. Patients who were undergoing any other concurrent anti-cancer treatments were also excluded. Patients’ data that were incompletely filled and the patients who lost to follow-up were also excluded.
The total patient source files collected after applying these criteria was 90. The patients were then divided into two arms according to the treatment they were given. Arm 1 included patients who had surgery followed by chemoradiation therapy (66 Gy), concurrent chemotherapy with Cisplatin; these patients came out to be 45. Arm 2 included patients who got induction chemotherapy with TPF protocol (docetaxel 75 mg/m^2 Day 1, cisplatin 75 mg/m^2 Day 1, and 5-FU 1000 mg/m^2 Days 2-5; 21 days cycle). Two to four cycles were given, after which radiation therapy 66 Gy was given; these were also 45 patients. Data of all the patients were recorded in a questionnaire (see the Appendix). The variables included patients’ demographics like age, sex, residential area, native language, substance abuse, and co-morbidity. Other variables include disease factors like the primary site of disease, lymph node involvement, and tumor staging. After completion of treatment, three-monthly follow-up data for 12 months was also recorded.

Outcomes were then recorded, which included progression-free survival (PFS), which is the primary outcome. This was defined as the first recurrence of disease noted clinically and/or radiologically after completion of the given treatment, and it was recorded in months. The other treatment result noted was the toxicity of treatment, and it included neutropenia and oral mucositis. These were recorded in terms of grading for each patient according to the criteria set by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 developed by the National Cancer Institute (NCI) US in 2017 [18]. These adverse events/toxicity were also stratified according to the number of cycles of chemotherapy given.

Later, after recording all the data, outcomes were then compared in both groups and the difference of mean PFS was found. To check the significance of this difference, the data were analyzed statistically using the independent sample t-test.

**Results**

**Descriptive results**

A total of 90 patients with squamous cell carcinoma of the oral cavity were enrolled in this study as a non-trial cohort, with 45 patients in each arm. The mean age of the patients was 46.73 (± 12.67) years. The mean ages of patients in Arm 1 and Arm 2 were 44.53 (± 11.34) and 48.93 (± 13.65) years, respectively, with no statistically significant difference (p-value, 0.09).

**Sex Distribution**

A total of 60 men and 30 women were included in the trial in both treatment groups (Figure 1).
Among all patients, 87 (96%) were from urban areas, whereas the remaining three lived in rural areas (Figure 2).
Sixty-three (63; 70%), nine (10%), nine (10%), three (3.33%), and six (6.66%) of the patients were Urdu, Balochi, Pushto, Gujrati, and Sindhi speaking, respectively (Figure 3).
FIGURE 3: Distribution of patients according to native language

**Substance Abuse**

Only 12 (13.3%) patients were not engaged in any substance abuse, whereas paan was the most commonly used substance (56.6%). Other common addictions were smoking (6.66%), supari/chalia (10%), gutka (6.66%), and niswar (6.66%). See Figure 4.
Comorbidities

Comorbidities (defined as having hypertension, diabetes mellitus, and kidney failure) were present in 15 (16.7%) patients (Figure 4).
Cancers originating in the cheeks were the most common primary site, with 51 (56.7%) patients with this type of tumor. Other sites included anterior tongue (21; 23.33%), posterior tongue (9, 10%), alveolus (6, 6.66%), and others (3, 3.33%). See Figure 6.
FIGURE 6: Distribution of primary site of the tumor

**Lymph Nodal Involvement**

A total of 84 (93.33%) patients had lymph nodal involvement in both arms (Figure 7).

FIGURE 7: Lymph nodal involvement in patients participating in the study

**Tumor Staging**
In Arm 1, 33 patients were stage IV-A and 12 patients were stage IV-B, whereas, in Arm 2, all 45 patients were stage IV-A (Figure 8).

![Pie chart showing tumor stage distribution](image)

**FIGURE 8: Distribution of tumor-node-metastasis staging in patients participating in the study**

**Inferential results**

**Toxicity Profile**

According to the data, it was evident that patients who received induction chemotherapy had apparent neutropenia and mucositis. The severity of neutropenia was dependent on the number of chemotherapy cycles administered. Furthermore, patients receiving chemoradiation did not develop neutropenia but had oral mucositis. See Table 1.
### TABLE 1: Comparisons of neutropenia and oral mucositis in patients of both arms

| Adverse events (with number of chemotherapy cycles) | Treatment arm (Frequency and percentage) | 1          | 2          |
|---------------------------------------------------|-----------------------------------------|------------|------------|
|                                                   | Grade of neutropenia                    |            |            |
|                                                   | 0                                      | 42 (93.33%)| 00         |
|                                                   | 1                                      | 03 (6.66%) | 00         |
|                                                   | 2                                      | 00         | 18 (40%)   |
|                                                   | 3                                      | 00         | 24 (53.33%)|
|                                                   | 4                                      | 00         | 03 (6.66%) |
|                                                   | Grade of oral mucositis                 |            |            |
|                                                   | 2                                      | 12 (26.66%)| 06 (13.33%)|
|                                                   | 3                                      | 15 (33.33%)| 12 (26.66%)|
|                                                   | 4                                      | 18 (40%)   | 27 (60%)   |
|                                                   | No of cycles of chemotherapy administered|            |            |
|                                                   | 0                                      | 45 (100%)  | 00         |
|                                                   | 2                                      | 00         | 18 (40%)   |
|                                                   | 3                                      | 00         | 21 (46.66%)|
|                                                   | 4                                      | 00         | 06 (13.33%)|

**Mean Progression-Free Survival (PFS)**

The mean PFS time of patients undergoing surgery followed by chemoradiation (Arm 1) is shown in Table 2. PFS was calculated according to the patients' comorbidity, primary disease site, lymph node status, and tumor-node-metastasis (TNM) stage.
| Characteristic            | Mean progression-free survival in months |
|--------------------------|------------------------------------------|
| Comorbidity              |                                          |
| Yes                      | 5.00                                     |
| No                       | 6.00                                     |
| Primary site             |                                          |
| Lips                     | --                                       |
| Cheeks                   | 6.00                                     |
| Anterior tongue          | 7.00                                     |
| Posterior tongue         | --                                       |
| Soft palate              | --                                       |
| Hard palate              | --                                       |
| Alveolus                 | --                                       |
| Floor of the mouth       | --                                       |
| Lymph node status        |                                          |
| Positive                 | 6.00                                     |
| Negative                 | --                                       |
| TNM stage                |                                          |
| IV-A                     | 6.00                                     |
| IV-B                     | --                                       |

**TABLE 2: Progression-free survival time in Arm 1**

The mean PFS of patients undergoing induction chemotherapy followed by radiation therapy (Arm 2) is shown in Table 3. PFS was calculated according to the patients' comorbidity, primary disease site, lymph node status, and TNM stage.
### TABLE 3: Progression-free survival time in Arm 2

| Characteristic              | Mean progression-free survival in months |
|-----------------------------|------------------------------------------|
| **Comorbidity**             |                                          |
| Yes                         | 8.00                                     |
| No                          | 7.00                                     |
| **Primary site**            |                                          |
| Lips                        | --                                       |
| Cheeks                      | 8.00                                     |
| Anterior tongue             | 7.00                                     |
| Posterior tongue            | 7.00                                     |
| Soft palate                 | --                                       |
| Hard palate                 | --                                       |
| Alveolus                    | 10.00                                    |
| Floor of the mouth          | --                                       |
| Lymph node status           |                                          |
| Positive                    | 8.00                                     |
| Negative                    | --                                       |
| **TNM stage**               |                                          |
| IV-A                        | 7.00                                     |
| IV-B                        | 10.00                                    |

Based on the results observed in Table 4, when comparing the two arms, there is no significant difference in the PFS between the standard arm and the experimental arm. Therefore, the study concurs with the international guidelines and does not prove any evident benefit of induction chemotherapy; however, a slight difference in favor of the experimental arm is observed, but at the cost of an increased toxicity profile, which concludes that in the upcoming era, we will achieve significant positive results in favor of the induction chemotherapy arm.

### TABLE 4: Comparison of progression-free survival times in both treatment arms

|                          | Arm 1 (surgery followed by concurrent chemoradiation therapy [66 Gy], chemotherapy with cisplatin) | Arm 2 (induction chemotherapy [2–4 cycles] with the docetaxel, cisplatin, and 5-fluorouracil protocol, followed by radiation therapy [66 Gy]) | p-value |
|--------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|---------|
| Progression-free survival time in months (mean ± standard deviation) | 6.40 ± 2.38                                                                                   | 7.60 ± 4.76                                                                                                   | 0.136   |

### Discussion

In a country such as Pakistan, patients with head and neck cancers are especially in the unfit group with relatively poor co-morbid conditions, lower socioeconomic status, and dismal educational levels. Considering the prevalence of paan, chalia, cigarette smoking, gutka, and naswar, the incidence of oral cancers has significantly increased. Ethnic disparities also exist in our study, as Urdu-speaking Karachiites are the largest consumers of paan and gutka. In our study, a little less than three-quarters of the patients...
belonged to this ethnic group.

According to previous studies, the most common site for oral squamous cell carcinoma is the buccal mucosa. Similarly, in Pakistan, the majority of cancers develop in the buccal mucosa. According to a study conducted by Yasmin Bhurgri in 2005, a total of 2,253 cases of oral cancer were registered in Karachi South during the eight-year study period (1995-2002). Oral cancers accounted for 8.8% of all cancer cases. Overall, the most common site was the buccal mucosa/cheek (55.9%), followed by the tongue (28.4%), palate (6.8%), gum (4.4%), lip (5.1%), and floor of the mouth (1.4%) [19].

In the present study, the PFS of patients in the experimental arm was higher than that in the standard arm, but the difference between the two groups was non-significant. Moreover, we also recorded lower PFS as compared to the previous literature, which shows the more aggressive nature of squamous cell carcinoma in this region as compared to the Western region. These results are consistent with the trial results reported by Alexander D. Rapids of Greece [20]. However, in this trial, there was no head-to-head comparison with the standard treatment arm. Furthermore, there are only a few trials comparing the standard of surgery and postoperative radiotherapy and experimental combination of induction chemotherapy followed by radiotherapy alone. In our study, the difference in PFS was not statistically significant between the two groups. This may be due to the smaller number of patients in our study, which might be unable to detect any benefit in the induction chemotherapy arm. Furthermore, shorter follow-up of the patients was also a limitation of our study, which rendered our results statistically insignificant.

Comparing the primary site of the tumor, there was a marginally insignificant difference (p = 0.054) in PFS time in patients with tumors of the cheek. However, comparing the results of PFS in patients with cancers of the anterior tongue, the results were insignificant.

Our study failed to provide any statistically significant evidence, pointing toward a potential role of induction chemotherapy followed by chemoradiotherapy compared to loco-regional treatment alone. This is supported by the results reported by Vokes et al. [21], who demonstrated that docetaxel-and cisplatin-based induction chemotherapy was beneficial in PFS in patients with head and neck cancers. This study, however, has conflicting results, but it still raises the possibility of the potential benefit of induction chemotherapy in oral cancers, which, in some cases, will generate good results if we have a larger-scale, multi-center RCT.

A clinical trial of a similar nature was conducted from February 2014 to October 2015 in three centers of Pakistan (Karachi, Multan, and Faisalabad), named the DECIDE study. The primary objective of this study was to evaluate the overall response rate (including complete response and partial response) of patients treated with combination therapy of docetaxel and cisplatin followed by chemoradiotherapy in patients with locally advanced head and neck cancer. This information was provided through personal communication by the principal investigator of the Karachi Center Professor Dr. S.H.M. Zaidi, which was later published [22]. The results showed a response rate of 68.6% in the induction chemotherapy arm with a manageable safety profile, but they also couldn’t report any patient with complete response. This study also supports that induction chemotherapy may help reduce the disease in some way, but it still can’t show the best response.

In regard to the limiting factor of the toxicity profile noted in our study, induction chemotherapy may still be tolerable if we apply some measures to reduce the adverse events. The major side effect of neutropenia may be prophylactically treated aggressively with granulocyte-colony stimulating factors (G-CSF); these are given as subcutaneous injections for five days after completion of chemotherapy. Other than this prophylactic antibiotics and care in regards to nutrition has to be taken to counter the immune-compromised state following chemotherapy. Furthermore, intravenous fluids for two to three days can also be supplemented to patients if they are nutritionally depleted. Similarly, oral mucositis may also be treated with antifungals and oral emollients. These measures may definitely help counter the adverse effects of chemotherapy, and we can then opt to give more induction chemotherapy and see if this will help us achieve further benefits in the management of oral cancers.

In our study setting, where resources are limited and the burden of cancers is growing, the majority of patients present with locally advanced disease, especially in head and neck cancers. In such a scenario, where there is an increased risk of local progression of disease due to delayed treatment in terms of delayed or incomplete surgery, induction chemotherapy is a promising modality to be added to the management of oral squamous cell carcinoma. Limiting the tumor after induction chemotherapy (ICT) helps in sparing normal tissue during radiotherapy planning.

Although it remains controversial whether ICT can improve OS, better PFS can assist in achieving a complete response in patients with head and neck cancers [23]. In the later phase, the OS of patients may also improve.

The inability of this study to determine any significant difference in PFS might also be due to the fact that the patients were non-trial cohort patients with comparability issues.
Conclusions

In this study, induction chemotherapy followed by radiation therapy did not show statistically significant results compared to the standard treatment; however, a slight difference in favor of the experimental arm was observed, but at the cost of increased toxicity profile, which concludes that in the upcoming era, we hope to achieve significant positive results in favor of induction chemotherapy.

Appendices

| HEAD AND NECK CANCER QUESTIONNAIRE |
|-------------------------------------|
| Serial Number                       |
| Name of the patient                 |
| MR number                           |
| Age of the patient                  |
| Sex                                 |
| Residential area                    |
| Native language                     |
| Substance abuse                     |
| Co-morbidities                      |
| Primary site of the disease         |
| Lymph node involvement (Yes/No)     |
| Group TNM stage                     |
| Neo-adjuvant chemotherapy given (Yes/No) |
| Cycles of chemotherapy              |
| Surgery done (Yes/No)               |
| Neutropenia during treatment (Grade 1-4) |
| Oral mucositis during treatment (Grade 1-4) |
| Treatment started on (Date)         |
| Treatment completed on (Date)       |
| Recurrence date                     |
| Progression-free survival (months)  |

TABLE 5: Study questionnaire

TNM: tumor-node-metastasis

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Ethical Review Committee, Ziauddin University issued approval 00401155SHONCO. Your study titled, "Induction Chemotherapy Followed By Radiation Therapy Versus Surgery Followed By Concurrent Chemo-Radiation Therapy In Locally Advanced Squamous Cell Carcinoma Of Oral Cavity" was reviewed by the ERC committee and as your study is a retrospective study and is a data analysis, has no human subjects or human tissue involved. ERC approval is not required/exempted.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years.
with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Petersen PE: Oral cancer prevention and control - the approach of the World Health Organization. Oral Oncol. 2009, 45:454-60. 10.1016/j.oraloncology.2008.05.023
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127:2895-917. 10.1002/ijc.25516
3. Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 2021, 71:7-33. 10.3322/caac.21654
4. Merchant A, Husain SS, Hosain M, et al.: Paan without tobacco: an independent risk factor for oral cancer. Int J Cancer. 2000, 86:128-51. 10.1002/(SICI)1097-0215(20000401)86:1<128::AID-IJC2>3.0.CO;2-M
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61:69-90. 10.3322/caac.20107
6. Jayalekshmi PA, Gangadharan P, Akisha S, Koriyama C, Nair RR: Oral cavity cancer risk in relation to tobacco chewing and bidi smoking among men in Karunagappally, Kerala, India: Karunagappally cohort study. Cancer Sci. 2011, 102:460-7. 10.1111/j.1349-7006.2010.01785.x
7. Lin MY, Chen MC, Wu IC, et al.: Areca users in combination with tobacco and alcohol use are associated with younger age of diagnosed esophageal cancer in Taiwanese men. PLoS One. 2011, 6:e25547. 10.1371/journal.pone.0025347
8. Binns C, Low WY, Hewitt K: Betel chewing and public health. Asia Pac J Public Health. 2011, 23:1021-4. 10.1177/1010539511426890
9. Wahid A, Ahmad S, Sajjad M: Pattern of carcinoma of oral cavity reporting at dental department of Ayub medical college. J Ayub Med Coll Abbottabad. 2005, 17:65-6.
10. Bhurgri Y, Bhurgri A, Nishter S, et al.: Pakistan--country profile of cancer and cancer control 1995-2004. J Pak Med Assoc. 2006, 56:124-30.
11. Jafarey NA, Zaidi SHM: Cancer in Pakistan. J Pak Med Assoc. 1987, 37:178-83.
12. Bile KM, Shahid A, Afridi HU, Khan Y: Smokeless tobacco use in Pakistan and its association with oropharyngeal cancer. East Mediterr Health J. 2010, 16 Suppl 5:24-30.
13. Arif Hasan, Mohib M: Understanding Slums: Case Studies for the Global Report on Human Settlements 2005, in Urban Slums Reports: The Case of Karachi, Pakistan. 2005.
14. The use of satellite images for urban planning: a case study from Karachi, Pakistan. (1989). https://documents.worldbank.org/en/publication/documents-reports/publication/86766146875511726/the-use-of-satell-
15. Pigson JF, le Malherbe A, Mailard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009, 92:4-14. 10.1016/j.radonc.2009.04.014
16. Lorch JH, Goloubeva O, Haddad RI, et al.: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011, 12:153-9. 10.1016/S1470-2045(10)70279-5
17. Ghi MG, Paccagnella A, Ferrari D, et al.: Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017, 28:2206-12. 10.1093/annonc/mdx299
18. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
19. Bhurgri Y: Cancer of the oral cavity - trends in Karachi South (1995-2002). Asian Pac J Cancer Prev. 2005, 6:22-6.
20. Rapiidis AD, Trichas M, Stavrinidis E, et al.: Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol. 2006, 42:675-84. 10.1016/j.oraloncology.2005.12.006
21. Vokes EE: Induction chemotherapy for head and neck cancer: recent data. Oncologist. 2010, 15 Suppl 3:5-7. 10.1615/Oncologist.v15.s03-5
22. Zaidi SHM, Manood AI, Shah SH, Hashemy I: Open label, non-randomized, interventional study to evaluate response rate after induction therapy with docetaxel and cisplatin in locally advanced squamous cell carcinoma of oral cavity. Gulf J Oncol. 2020, 1-12-28.
23. Haddad R, O'Neill A, Rabinovits G, et al.: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013, 14:257-64. 10.1016/S1470-2045(13)70011-1